Veritas Announces Completion of Clinical Trial on Cannabis Product for Treatment of Acute Pain

The clinical trial was designed as a randomized, double-blinded, cross-over trial and tested the efficacy of vaporized CTL-X for the treatment of acute pain in healthy adult subjects.

Subscribe

SAN JUAN, Puerto Rico, May 15, 2019 (GLOBE NEWSWIRE) -- PRESS RELEASE -- Veritas Pharma Puerto Rico, Inc., a wholly owned subsidiary of Veritas Pharma Inc. has announced the completion of its clinical trial on its lead cannabis treatment (CTL-X) for acute pain. The clinical trial was designed as a randomized, double-blinded, cross-over trial and tested the efficacy of vaporized CTL-X for the treatment of acute pain in healthy adult subjects.

FDI Clinical Research, a San Juan-based clinical research organization, conducted the studied following GMP standards. Veritas' Medical Director Dr. Scott Alexander and FDI’s CEO Dr. Jose F. Rodriguez Orengo designed andcarried out this study to obtain clinical data on the safety and potential efficacy of CTL-X in acute pain.

During the next three months, Veritas and FDI will analyze the data and submit a scientific manuscript for publication addressing the key outcomes from the trial including:

  • Preliminary efficacy data on CTL-X compared to placebo
  • Guidelines on dosage
  • Safety and tolerability data, such as side effects and adverse events, associated with CTL-X

Alexander commented, “From this study, we will be able to provide real scientific and evidence-based data on the use of cannabis for medical purposes for treatment of acute pain. We believe that for millions of people suffering from acute pain vaporized cannabis can potentially reduce the need for other medications, including opioids. From results of this study, clinicians will have a better understanding for specific dosage and delivery of cannabis for acute pain. Additionally, our data will encourage further research to further quantify possible risks and valid functional benefits of whole plant cannabinoids as a complementary therapeutic approach in medicine.”

Furthermore, Veritas would like to announce granting of 1,200,000 options to the company’s interim CEO/CFO and directors under the stock option plan at an exercise price of $0.52 for a period of five years from the date of the grant.